Argenx SE is a biotechnology firm based in Amsterdam, focusing on developing treatments for autoimmune diseases. Its flagship product, efgartigimod, aims to help patients with conditions like myasthenia gravis and pemphigus vulgaris. Beyond efgartigimod, Argenx is working on a range of therapies targeting severe autoimmune diseases and airway inflammation. The company collaborates with global partners, including AbbVie and Zai Lab, to advance its research and bring innovative therapies to market.
Wall Street analysts are reshuffling their bets ahead of a critical inflation report and NVIDIA earnings that could jolt markets in either direction. Find out which names got upgraded, cut, or newly…
Pre-Market Stock Futures: Futures are trading higher on Thursday as we grind closer to the Christmas holiday, which is just a week off now. The song remains the same for the AI/Datacenter…
